Coumarins effectively inhibit bacterial α-carbonic anhydrases
- PMID: 34979838
- PMCID: PMC8741243
- DOI: 10.1080/14756366.2021.2012174
Coumarins effectively inhibit bacterial α-carbonic anhydrases
Abstract
Coumarins are known to act as prodrug inhibitors of mammalian α-carbonic anhydrases (CAs, EC 4.2.1.1) but they were not yet investigated for the inhibition of bacterial α-CAs. Here we demonstrate that such enzymes from the bacterial pathogens Neisseria gonorrhoeae (NgCAα) and Vibrio cholerae (VchCAα) are inhibited by a panel of simple coumarins incorporating hydroxyl, amino, ketone or carboxylic acid ester moieties in various positions of the ring system. The nature and the position of the substituents in the coumarin ring were the factors which strongly influenced inhibitory efficacy. NgCAα was inhibited with KIs in the range of 28.6-469.5 µM, whereas VchCAα with KIs in the range of 39.8-438.7 µM. The two human (h)CA isoforms included for comparison reason in the study, hCA I and II, were less prone to inhibition by these compounds, with KIs of 137-948.9 µM for hCA I and of 296.5-961.2 µM for hCA II, respectively. These findings are relevant for discovering coumarin bacterial CA inhibitors with selectivity for the bacterial over human isoform, with potential applications as novel antibacterial agents.
Keywords: Carbonic anhydrase; Neisseria gonorrhoeae; antibacterials; coumarins; inhibitor.
Conflict of interest statement
CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Figures
References
-
- (a) Smith KS, Jakubzick C, Whittam TS, Ferry JG.. Carbonic anhydrase is an ancient enzyme widespread in prokaryotes. Proc Natl Acad Sci U S A 1999;96:15184–9. - PMC - PubMed
- (b) Abuaita BH, Withey JH.. Bicarbonate induces Vibrio cholerae virulence gene expression by enhancing ToxT activity. Infect Immun 2009;77:4111–20. - PMC - PubMed
- (c) Merlin C, Masters M, McAteer S, Coulson A.. Why is carbonic anhydrase essential to Escherichia coli? J Bacteriol 2003;185:6415–24. - PMC - PubMed
- (d) Del Prete S, Nocentini A, Supuran CT, Capasso C.. Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem 2020;35:1060–8. - PMC - PubMed
-
- (a) Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34. - PMC - PubMed
- (b) Flaherty DP, Seleem MN, Supuran CT.. Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med Chem 2021;13:1619–22. - PMC - PubMed
- (c) Petreni A, De Luca V, Scaloni A, et al. . Anion inhibition studies of the Zn(II)-bound ι-carbonic anhydrase from the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem 2021;36:372–6. - PMC - PubMed
- (d) Supuran CT, Capasso C.. An Overview of the Bacterial Carbonic Anhydrases. Metabolites 2017;7:56. - PMC - PubMed
-
- (a) Supuran CT, Capasso C.. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat 2018;28:745–54 - PubMed
- (b) Supuran CT, Capasso C.. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat 2020;30:963–82. - PubMed
- (c) Campestre CD, Luca V, Carradori S, et al. . Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol 2021;12:629163. - PubMed
- (d) Capasso C, Supuran CT.. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem 2015;30:325–32. - PubMed
-
- (a) Kaur J, Cao X, Abutaleb NS, et al. . Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus. J Med Chem 2020;63:9540–62. - PMC - PubMed
- (b) Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN.. In vivo antibacterial activity of acetazolamide. Antimicrob Agents Chemother 2021;65:e01715–20. - PMC - PubMed
- (c) Abutaleb NS, Elhassanny AEM, Flaherty DP, Seleem MN.. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ 2021;9:e11059. - PMC - PubMed
-
- (a) Hewitt CS, Abutaleb NS, Elhassanny AEM, et al. . Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis 2021;7:1969–84. - PMC - PubMed
- (b) Nocentini A, Hewitt CS, Mastrolorenzo MD, et al. . Anion inhibition studies of the α-carbonic anhydrases from Neisseria gonorrhoeae. J Enzyme Inhib Med Chem 2021;36:1061–6. - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical